^
Association details:
| Biomarker: | TP53 mutation + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
70P - Impact of TP53/KRAS mutations on Overall Survival of Metastatic non-Small Cell Lung Cancer Patients (pts) Treated with Systemic First-line Therapy
Published date:
03/23/2023
Excerpt:
There was a significant OS benefit in TP53 mutated pts with PDL1 < 50% (HR: 0.44; 95%CI: 0.20–0.98; p = 0.043)…We observed a statistically significant difference in OS favouring pts with TP53 mutations in the PDL1 < 50% population….TP53 mutations could represent a potential biomarker for treatment selection for pts with low PDL1 expression treated with chemo-immunotherapy.
